[FETV=박제성 기자] Fugenbio announced that the research result of ‘Serliporia lock Serrata’ mycelium not only improving diabetes but also suppressing the pathology related to symptoms in animals that caused cognitive impairment was published in ‘Food science & biotechnology’, an SCI-level international academic journal 8 work said
‘Dietary supplementation with Ceriporia lacerata improves learning and memory in a scopolamine-induced amnesia mouse, jointly studied with Kyungpook National University’s Professor Kim Sang-sang’s research team In the thesis titled ‘, the research team confirmed that Cereporia rock Serrata showed effects such as improving memory and cognitive ability, and alleviating hippocampal tissue damage.
As pharmacological mechanisms of action, free radical scavenging activity, oxidative stress suppression, and antioxidant enzyme-induced activation effect were investigated. This suggests that the brain nerve cell protective effect of S. Lipo Ria lock Serrata, which is differentiated from existing substances, can be linked to the effect of improving the cognitive function of the human body.
Kim Jung-hwan, head of Fugenbio’s research division, said, “This study confirmed the potential inhibitory effect of C. lock serrata from Alzheimer’s disease, which occurs when insulin resistance induces amyloid beta plaque, inflammation and oxidative stress in the brain. It presents new possibilities as therapeutic substances.”
According to ‘JAMA Neurology 2016’, a study conducted by Dr. Sanjay Asthana at the University of Wisconsin, USA, insulin resistance causes cognitive decline. In particular, when glucose metabolism decreases, cognitive function-related areas decrease and the risk of Alzheimer’s disease increases. did. In other words, if the brain does not use enough fuel due to insulin resistance, the memory deteriorates and interferes with daily life, which in turn can lead to Alzheimer’s disease.
According to the International Association for Alzheimer’s Disease (ADI), the number of dementia patients worldwide increased from 46.78 million in 2015 to 50 million in 2018, an increase of 3 million in three years. ADI predicts that the number of dementia patients will continue to increase from 75 million in 2030 to 131.5 million in 2050.
Dementia drugs on the market are largely divided into acetylcholinesterase inhibitors and NMDA receptor antagonists depending on the mechanism of development. There are three types of acetylcholinesterase inhibitors: donepezil, rivastigmine, and galantamine, and memantine is an NMDA receptor antagonist. These four drugs do not restore damaged nerve cells, but are known to help maintain cognitive function and delay disease progression.
Since brain cells, once damaged, cannot be regenerated, protection of brain cells from damage is the only solution at present, for which no special treatment has been developed. The protective effect on the brain nerve cells of S. Lipo Ria lock Serrata revealed through this study is of great significance.
.
